AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Celularity Announces Full Year 2024 Operating and Financial Results
Fri 09 May 25, 01:15 PM| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -57.89200M | -196.28500M | 14.21M | -100.09800M | -212.93300M |
| Minority interest | - | - | - | - | - |
| Net income | -57.89200M | -196.29500M | 14.19M | -100.11800M | -208.23300M |
| Selling general administrative | 58.62M | 50.58M | 66.02M | 71.34M | 31.34M |
| Selling and marketing expenses | 0.02M | - | - | - | - |
| Gross profit | 39.23M | 6.75M | -1.69000M | 11.68M | 9.35M |
| Reconciled depreciation | 7.92M | 9.32M | 9.44M | 8.82M | 8.17M |
| Ebit | -51.62800M | - | -25.60000M | -148.01200M | -78.09100M |
| Ebitda | -43.70600M | - | -141.13500M | -96.92700M | -65.45100M |
| Depreciation and amortization | 7.92M | - | -115.53500M | 51.09M | 12.64M |
| Non operating income net other | - | - | - | - | -44.84869M |
| Operating income | -38.35800M | -76.47900M | -25.60000M | -148.01200M | -78.09100M |
| Other operating expenses | 92.58M | - | 166.24M | 169.35M | 92.37M |
| Interest expense | 6.26M | 3.02M | -164.77600M | 3.17M | 2.35M |
| Tax provision | 0.00000M | 0.01000M | 0.01M | 0.02M | -4.70000M |
| Interest income | 0.33M | 0.32M | 0.36M | 0.33M | 0.37M |
| Net interest income | -5.93300M | -2.69500M | 0.36M | -2.83900M | -1.98400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.01000M | - | 0.01M | 0.02M | -4.70000M |
| Total revenue | 54.22M | 22.77M | 17.98M | 21.34M | 14.28M |
| Total operating expenses | 77.59M | 99.25M | 146.58M | 159.69M | 87.44M |
| Cost of revenue | 14.99M | 16.02M | 19.66M | 9.65M | 4.93M |
| Total other income expense net | -19.53400M | -117.11100M | 39.80M | 47.91M | -134.84200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -57.89200M | -196.29500M | 14.19M | -100.11800M | -49.26030M |
| Net income applicable to common shares | - | - | 14.19M | -100.11800M | -49.26030M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 132.68M | 143.89M | 401.07M | 414.13M | 431.01M |
| Intangible assets | 9.25M | 11.00M | 120.99M | 123.19M | 125.38M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.86M | 0.33M | 9.78M | 0.00200M | 0.87M |
| Total liab | 123.84M | 102.93M | 202.16M | 314.71M | 962.41M |
| Total stockholder equity | 8.84M | 40.96M | 198.90M | 99.42M | -531.40000M |
| Deferred long term liab | - | - | - | - | 0.00060M |
| Other current liab | 20.49M | 2.45M | 16.40M | 11.66M | 13.45M |
| Common stock | 0.00200M | - | 0.01M | 0.01M | 0.00100M |
| Capital stock | 0.00200M | 0.02M | 0.01M | 0.01M | 0.00100M |
| Retained earnings | -899.68300M | -841.79100M | -645.49600M | -663.68100M | -563.56300M |
| Other liab | - | - | 112.09M | 260.40M | 357.98M |
| Good will | 7.35M | 7.35M | 119.69M | 123.30M | 123.30M |
| Other assets | - | - | - | 17.91M | 20.09M |
| Cash | 0.74M | 0.23M | 13.97M | 37.24M | 54.31M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 53.68M | 67.30M | 62.09M | 26.23M | 26.68M |
| Current deferred revenue | 3.53M | - | 2.27M | 2.20M | 4.83M |
| Net debt | 68.10M | 39.01M | 51.62M | -6.10400M | -23.66900M |
| Short term debt | 6.36M | - | 37.60M | 3.05M | 3.01M |
| Short long term debt | 6.36M | 39.24M | 37.60M | - | - |
| Short long term debt total | 68.84M | - | 65.59M | 31.14M | 30.64M |
| Other stockholder equity | 908.52M | - | 443.31M | 763.09M | 32.16M |
| Property plant equipment | - | - | - | 90.62M | 90.08M |
| Total current assets | 20.56M | 19.79M | 33.50M | 37.24M | 72.16M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | -41.78700M | -147.07300M | 214.13M |
| Short term investments | - | - | - | - | - |
| Net receivables | 13.56M | 10.05M | 6.97M | 5.23M | 6.55M |
| Long term debt | 35.93M | - | - | - | - |
| Inventory | 5.41M | 5.75M | 5.31M | 9.55M | 3.85M |
| Accounts payable | 23.30M | 14.14M | 5.81M | 9.32M | 5.39M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.00500M | - | 0.00900M | -414.12800M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 272.93M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | -43.38262M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 12.86M | 26.93M | 38.15M | 39.77M | 20.09M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 112.12M | 124.10M | 367.56M | 376.89M | 358.85M |
| Capital lease obligations | 26.55M | 26.18M | 27.98M | 31.14M | 30.64M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 0.51M | -4.04800M | -5.23600M | -5.90300M | -0.13750M |
| Change to liabilities | - | - | -2.94800M | -5.37500M | 3.18M |
| Total cashflows from investing activities | 0.51M | - | -5.23600M | -5.90300M | 0.58M |
| Net borrowings | -13.89800M | -14.81100M | - | - | - |
| Total cash from financing activities | 6.70M | 24.09M | 119.84M | 98.56M | 102.01M |
| Change to operating activities | - | - | - | 2.62M | -1.81200M |
| Net income | -57.89200M | -196.29500M | 14.19M | -100.11800M | -208.23300M |
| Change in cash | 0.81M | -18.63900M | -23.27400M | -17.43700M | 26.01M |
| Begin period cash flow | 10.16M | 28.80M | 52.08M | 69.51M | 43.51M |
| End period cash flow | 10.98M | 10.16M | 28.80M | 52.08M | 69.51M |
| Total cash from operating activities | -6.40100M | -38.68500M | -137.87600M | -110.09600M | -63.19300M |
| Issuance of capital stock | 6.00M | 21.89M | 36.52M | 83.40M | 102.53M |
| Depreciation | 7.92M | 9.32M | 9.44M | 8.82M | 8.17M |
| Other cashflows from investing activities | 2.17M | - | - | 0.30M | 0.72M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 6.28M | -0.86500M | -16.89100M | -6.42200M | -0.64300M |
| Change to account receivables | -3.96800M | -6.82700M | -3.58400M | -1.90900M | 1.65M |
| Sale purchase of stock | - | - | - | 0.00000M | -0.25600M |
| Other cashflows from financing activities | -0.45900M | - | 83.32M | 20.16M | 102.27M |
| Change to netincome | - | - | - | -7.71200M | 46.63M |
| Capital expenditures | 0.16M | 4.05M | 5.24M | 6.20M | 27.83M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | -1.73151M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | -0.60231M |
| Change in working capital | 22.20M | 3.25M | -17.97600M | -11.08300M | 3.60M |
| Stock based compensation | 11.57M | 15.02M | 15.86M | 40.01M | 4.37M |
| Other non cash items | 9.80M | -92.31400M | -159.38300M | -46.36900M | 137.37M |
| Free cash flow | -6.56200M | -42.73300M | -143.11200M | -116.29900M | -91.02700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CELU Celularity Inc |
-0.0582 7.68% | 0.70 | - | - | 0.87 | 9.89 | 2.52 | -36.7779 |
| NVO Novo Nordisk A/S |
1.54 3.36% | 47.42 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.63 0.35% | 468.42 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
5.53 0.90% | 618.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
170 Park Avenue, Florham Park, NJ, United States, 07932
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, CEO & Chairman | 1959 |
| Mr. John R. Haines | Sr. EVP, GM & Chief Admin. Officer | 1957 |
| Mr. David C. Beers C.F.A., CFA | Chief Financial Officer | 1970 |
| Dr. Bradley Glover Ph.D. | Exec. VP & COO | 1969 |
| Mr. Tim Wilk | Sr. VP of Technical Operations | NA |
| Carlos Ramirez | SVP of Investor Relations | NA |
| Mr. Keary R. Dunn Esq. | EVP, Gen. Counsel, Chief Legal Officer & Head of Bus. Devel. | 1970 |
| Ms. Beth Steinbrenner | Exec. VP of HR | NA |
| Dr. Stephen A. Brigido D.P.M. | Pres of Degenerative Diseases | 1976 |
| Dr. Anne Jones Ph.D. | Exec. VP & Chief Bus. Officer | 1971 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...